- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Turing to lower price of Daraprim amid controversy
23 September 2015 • Author: Victoria White
Turing Pharmaceuticals, the company that faced a backlash in the US after increasing the price of Daraprim by over 5000%, has said that the price of the drug will be lowered.
Turing raised the price of the drug from $13.50 per tablet to $750 per tablet. In the UK, Daraprim is available from GSK at a cost of US $20 (£13) for 30 tablets.
However, in an interview with ABC News yesterday, Martin Shkreli, CEO of Turing, said, “We’ve agreed to lower the price on Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.”
The Company has not confirmed what the new price will be.
Daraprim is the only FDA-approved treatment for toxoplasmosis, when used in combination with a sulfonamide and leucovorin. Toxoplasmosis is a parasitic infection which affects people with compromised immune systems.
The Company has said that it plans to use money made from Daraprim to improve on the current formulation of the drug and seek to develop new therapeutics for the treatment of toxoplasmosis.
In a separate interview with Bloomberg, Shkreli commented on his Company’s plans: “We are spending tens of millions of dollars to make a better version of Daraprim that is more effective, less toxic – Daraprim is very toxic – and these patients deserve a drug company that is turning a profit, a fair profit, and also developing a drug that is better for them. They don’t deserve a drug that is 70 years old. They deserve a modern medicine that can cure toxoplasmosis quickly.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics